Navigation Links
Results of the PEPCAD-DES trial reported at TCT 2011
Date:11/11/2011

SAN FRANCISCO, CA NOVEMBER 11, 2011 A clinical trial of patients with restenosis in drug-eluting stents (DES) in native coronary arteries found that treatment with paclitaxel-coated balloon angioplasty demonstrated superior results over plain old uncoated-balloon angioplasty (POBA). Results from the PEPCAD-DES clinical trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

The incidence of drug-eluting stent restenosis (DES-ISR) remains frequent due to the continuous increase in DES implantations. Treatment of in-stent restenosis (ISR) with an additional stent implantation adds another metal layer within the coronary arteries, abolishing the physiologic vasoreactivity of the vessel. Drug-eluting stents significantly reduce the occurrence of restenosis and the subsequent need for repeat vascularization.

Paclitaxel eluting-balloon angioplasty has been shown to be superior to POBA for the treatment of ISR in bare-metal stents (BMS). Whether it is also effective in ISR of different drug-eluting stents has not been extensively studied so far. The PEPCAD DES trial compared the efficacy of the paclitaxel-eluting balloon catheter for treatment of ISR in DES in native coronary arteries to uncoated balloon angioplasty to methodologically assess the efficacy of the balloon mediated drug coating.

This randomized, multicenter, single blinded trial was conducted at six centers and included 110 patients with ISR of DES in multiple stent types. They were divided into two treatment groups: 72 for drug-coated balloon (DCB) angioplasty and 38 for POBA to achieve 90% power. Inclusion criteria were: lesion in native coronary artery, DES restenosis of sirolimus-eluting, everolimus-eluting, or paclitaxel-eluting stents, indication for percutaneous coronary intervention, reference diameter ranging from 2.5 mm to 3.5 mm and a lesion length le
'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Results of the STACCATO Trial reported at TCT 2011
2. Results of the DEB-AMI Trial reported at TCT 2011
3. Results of the RIFLE STEACS clinical trial reported at TCT 2011
4. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
5. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
6. Combination epigenetic therapy clinical trial results
7. Results of the PARIS registry Reported at TCT 2011
8. Results of the TRIGGER-PCI trial reported at TCT 2011
9. Results of rapid gene trial reported at TCT 2011
10. Results of the BRIDGE trial reported at TCT 2011
11. First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 The holidays are here, and with ... Many may be thinking about how to enjoy these events ... weeks. Health Republic Insurance of New York has compiled some ... to provide some smart ideas to enjoy the holiday festivities ... arriving at a holiday gathering over-hungry , Have a light ...
(Date:12/22/2014)... New York, NY (PRWEB) December 22, 2014 ... out 2014 stronger than ever, having invested more ... post-9/11 injured service members, veterans and their families. ... today for nearly a dozen nonprofits, helping with: ... peer-support; nursing scholarships; and life-coaches for severely injured ...
(Date:12/22/2014)... December 22, 2014 In recognition of ... sales to Hero Reward, a local organization that provides ... , Located on a couple hundred acres ... Program offers lodging, world class fishing, hunting, hiking, horseback ... was founded several years ago to support U.S. Service ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 TheHardwareCity.com now ... glove with many useful features. Customers of the large ... have the new gloves delivered to their home or ... and hand tools that incorporate heavy duty magnets, which ... Glove allows workers to store metal parts on the ...
(Date:12/22/2014)... December 21, 2014 A substantial ... chest computed tomography (CT) to evaluate abnormal findings ... including cancer, according to a new study published ... said the findings show that radiologist recommendations for ... contributions to patient care. , RAIs, which have ...
Breaking Medicine News(10 mins):Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3
... Russian President Vladimir Putin to Adopt a National ... Plan ... Cancer, a cancer,patient advocacy group in Russia, today launched an effort ... in Russia to innovative and effective treatments, including,diagnostic procedures and the ...
... Public Services, Inc.,a subsidiary of SAP AG (NYSE: ... vice,president of its U.S. healthcare practice. The appointment ... initiatives to improve the quality and delivery of,healthcare ... for growing,SAP,s business in the U.S. healthcare sector ...
... Joyce Erony Joins Board of Directors -, PALO ... device company that is developing a new category of ... that,it has raised $21 million in a Series C ... also announced that Joyce Erony,managing director of Signet Healthcare ...
... FRANKLIN LAKES, N.J., Feb. 4 Medco Health,Solutions, Inc. ... and,full-year 2007 financial results in a press release before ... the release, management will hold a conference call to ... a.m. ET., To access the live conference call ...
... is the First and Only Inhaled Corticosteroid approved for ... Once-Daily dosing in Children as Young as Age 4, ... today announced that the U.S. Food and Drug,Administration (FDA) has ... for the maintenance treatment of,asthma as a preventive therapy in ...
... Cherries, May Help Protect Your Heart, LANSING, Mich., ... universal mantras for promoting heart-health during February,American Heart Month. ... eating red to protect our hearts. Americans are encouraged ... the first-ever National,Eat Red Week, Feb. 4-10., Why ...
Cached Medicine News:Health News:Movement Against Cancer, a Cancer Patient Advocacy Group in Russia, Launches an Effort to Inform Russian Authorities and the Public About Inadequate Access of Innovative and Effective Cancer Treatments for Cancer Patients in Russia 2Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 2Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 3Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 4Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 5Health News:PEAK Surgical, Inc. Closes $21 Million Series C Financing 2Health News:Medco Announces Date for Fourth-Quarter and Full-Year 2007 Financial Results 2Health News:FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11 2Health News:FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11 3Health News:FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11 4Health News:FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11 5Health News:FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11 6Health News:Celebrate American Heart Month by Eating Red 2Health News:Celebrate American Heart Month by Eating Red 3
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... of the "Investment Analysis of the US ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... US medical device sector identifies the key trends ... capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
(Date:12/22/2014)... , Dec. 22, 2014  Relmada Therapeutics, Inc. ... for the treatment of chronic pain, announced today ... dosed in a pharmacokinetic and pharmacodynamic study with ... neuropathic pain. Racemic methadone is a ... pain states and substitution therapy in opioid addiction.  ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... Data Provides Ophthalmologists Critical Insight on Novel Beta ... Radiation Epiretinal Therapy, ... a one-year feasibility study of the company,s novel beta,radiation epiretinal therapy ... Annual Meeting of the American Academy of,Ophthalmology in New Orleans, Louisiana. ...
... Two studies being presented at the,American Academy ... have a significant role to play in the ... access to quality care. In the first ... patients with diabetes being treated in multi-physician primary ...
Cached Medicine Technology:NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO 2NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO 3Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease 2Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease 3
Semi-Automated Chemistry Analyzer with model screen master. The Screen Master incorporates many powerful features in one compact unit. Useful for biochemical investigations, enzymatic, immunoturbidi...
... Hema-G Stains for Geometric Data ... performance. Stains are quality control ... to ensure proper staining and ... most applications for a minimum ...
... fast, single-solution staining, Hema-Quik II ... slides into stain solution for ... to deionized water for five ... second time by dipping quickly ...
This stain is the McNeal formula and can be substituted for Wright Stain solution....
Medicine Products: